| 1 |
Landuzzi L, Ruzzi F, Lollini PL, Scotlandi K. Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research. Cancers (Basel) 2023;15. [PMID: 36765545 DOI: 10.3390/cancers15030588] [Reference Citation Analysis]
|
| 2 |
Jiménez JA, Lawlor ER, Lyssiotis CA. Amino acid metabolism in primary bone sarcomas. Front Oncol 2022;12:1001318. [PMID: 36276057 DOI: 10.3389/fonc.2022.1001318] [Reference Citation Analysis]
|
| 3 |
Meister MT, Groot Koerkamp MJA, de Souza T, Breunis WB, Frazer-Mendelewska E, Brok M, DeMartino J, Manders F, Calandrini C, Kerstens HHD, Janse A, Dolman MEM, Eising S, Langenberg KPS, van Tuil M, Knops RRG, van Scheltinga ST, Hiemcke-Jiwa LS, Flucke U, Merks JHM, van Noesel MM, Tops BBJ, Hehir-Kwa JY, Kemmeren P, Molenaar JJ, van de Wetering M, van Boxtel R, Drost J, Holstege FCP. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes. EMBO Mol Med 2022;14:e16001. [PMID: 35916583 DOI: 10.15252/emmm.202216001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 4 |
Lanzi C, Cassinelli G. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas. Biochemical Pharmacology 2022;198:114944. [DOI: 10.1016/j.bcp.2022.114944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Martella E, Dozza B, Ferroni C, Obeyok CO, Guerrini A, Tedesco D, Manet I, Sotgiu G, Columbaro M, Ballestri M, Martini L, Fini M, Lucarelli E, Varchi G, Duchi S. Two Beats One: Osteosarcoma Therapy with Light-Activated and Chemo-Releasing Keratin Nanoformulation in a Preclinical Mouse Model. Pharmaceutics 2022;14:677. [DOI: 10.3390/pharmaceutics14030677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Meister MT, Groot Koerkamp MJA, de Souza T, Breunis WB, Frazer-mendelewska E, Brok M, Demartino J, Manders F, Calandrini C, Kerstens HHD, Janse A, Dolman MEM, Eising S, Langenberg KPS, van Tuil M, Knops RRG, van Scheltinga ST, Hiemcke-jiwa LS, Flucke U, Merks JHM, van Noesel MM, Tops BBJ, Hehir-kwa JY, Kemmeren P, Molenaar JJ, van de Wetering M, van Boxtel R, Drost J, Holstege FCP. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.. [DOI: 10.1101/2022.01.03.474504] [Reference Citation Analysis]
|
| 7 |
Damerell V, Pepper MS, Prince S. Molecular mechanisms underpinning sarcomas and implications for current and future therapy. Signal Transduct Target Ther 2021;6:246. [PMID: 34188019 DOI: 10.1038/s41392-021-00647-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
|
